“Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?”, Can IBD Today, vol. 1, no. S05, pp. 2–7, May 2023, doi: 10.58931/cibdt.2023.1S0510.